Zobrazeno 1 - 2
of 2
pro vyhledávání: '"P Gabaldon Garnica"'
Autor:
L González del Valle, C Sobrino Jiménez, F Moreno Ramos, A Herrero Ambrosio, C Jimenez Vicente, P Gabaldon Garnica
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Alirocumab and evolocumab are monoclonal antibodies that belong to a new class of cholesterol-lowering drugs by inhibiting the proprotein convertase subtilisin/kexin type-9 (PCSK9) enzyme. Purpose The main objective of this study was to ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5b043ef5dee99feb6251206ad19e90d
https://doi.org/10.1136/ejhpharm-2019-eahpconf.175
https://doi.org/10.1136/ejhpharm-2019-eahpconf.175
Autor:
J Alvarez Criado, A Herrero Ambrosio, C Jimenez Vicente, C Jimenez Nunez, P Lucena Martinez, P Gabaldon Garnica, T Perez Robles, M Moreno Palomino
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Lysosomal acid lipase deficiency (LALD) is a rare lysosomal disorder characterised by clinical with dyslipidaemia and steatohepatitis. Sebelipase-alfa is a recombinant human LAL, recently approved for clinical use in LALD. Purpose Evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb2ae664b065d1bac8a360e93e70bdcb
https://doi.org/10.1136/ejhpharm-2019-eahpconf.440
https://doi.org/10.1136/ejhpharm-2019-eahpconf.440